SCHEMBL975362

SCHEMBL975362

NC(=O)c1cc2cc(C(F)(F)F)cnc2n1Cc1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
GRIN1 Q05586 3/20 0.44
GRIN2B Q13224 3/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
ATM Q13315 1/20 0.43
PLA2G10 O15496 2/20 0.41
F10 P00742 3/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PPARG P37231 2/20 0.39
F2 P00734 1/20 0.39
CNR1 P21554 1/20 0.38
PLA2G2A P14555 1/20 0.38
PLA2G5 P39877 1/20 0.38
GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974497 0.90 CCR2 (0.46) GRIN1GRIN2BKDM4ECYP1A2CYP3A4
SCHEMBL1093477 0.85 MAPT (0.46) KMT2AGRIN1GRIN2BKDM4ECYP1A2
SCHEMBL1100150 0.82 ECE1 (0.45) GRIN1GRIN2BKDM4EF10MAPT
SCHEMBL1099566 0.82 KCNQ3 (0.48) GRIN1GRIN2BCYP1A2CYP3A4CYP2C19
SCHEMBL973793 0.82 MAOB (0.40) GRIN1GRIN2BKDM4ECYP1A2CYP3A4
SCHEMBL974748 0.81 CCR2 (0.55) PLA2G10F10PPARGPLA2G2APLA2G5
SCHEMBL4382390 0.81 ATM (0.61) KMT2AKDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL1099550 0.81 GRIN1 (0.42) USP2GRIN1GRIN2BKDM4ECYP1A2
SCHEMBL1100149 0.80 KCNQ3 (0.49) GRIN1GRIN2BCYP1A2CYP3A4CYP2C19
SCHEMBL1099650 0.80 PPARG (0.40) GRIN1GRIN2BKDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2235016-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-09-18 EP disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF XDH, NQO2, SLC28A2 KMT2A 648/4885USP2 3020/4885GRIN1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.